Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- (-) Formulary Development
- (-) Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- (-) Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 46 Results
Ready, Fire, Aim: How Not to Approach COVID Pricing Discussions
NPC raises concerns about various approaches to considering pricing for COVID-19 treatments.
Do Patient Preferences Align with Value Frameworks? A Discrete-Choice Experiment of Patients with Breast Cancer
The study assessed patient preferences for aspects of breast-cancer treatments to evaluate the usual assumptions in scoring rubrics for value frameworks.
Evolution of the AMCP Format for Formulary Submissions: Yesterday, Today and Tomorrow
The ongoing development of vaccines and treatments for COVID-19 is raising hopes as the world awaits the return to a normal way of life. But as seen in the past decades in the fight against cancer,…
NPC in Health Affairs: It's Time to Talk COVID-19 Treatment Prices
In an article on the Health Affairs Blog, National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois considers questions about COVID-19 treatments and prices and lays out a roadmap to…
Will the Pandemic Provide the Push for Positive Change?
NPC President and CEO Dan Leonard considers the COVID-19 pandemic and its impact on our health care system, as well as whether we’ll see continued innovation in how we access, administer and pay for…
Underestimating the Value of an Intervention – The Case for Including Productivity in Value Assessments and Formulary Design
Research shows that including non-health care costs like productivity in value assessment frameworks can change the value assessment of interventions, impact on coverage decisions and subsequent…
Experts Advise Including Productivity in Value Assessment Frameworks – When Included, It Can Make a Difference
NPC researchers sought to assess if productivity is included in VAF analyses, when included, does it change the value assessment of an intervention, and if including productivity could change health…
Valuing Innovation in the Current and Post-Pandemic World
Biopharmaceutical industry experts gathered for a panel discussion at the eyeforpharma Virtual Conference to explore how the value of innovation, productivity and preparedness might change as a…
In Social Distancing, Finding Closeness in Community
In a video, National Pharmaceutical Council President and CEO Dan Leonard discusses social distancing and the importance of community during the COVID-19 pandemic.
What's Really Behind Discrepancies in Coverage Decisions?
National Pharmaceutical Council President and CEO Dan Leonard discusses research that uncovers the reasons for discrepancies in coverage decisions.
NPC Submits Comments on Cures 2.0
The National Pharmaceutical Council (NPC) submitted comments in response to a public request for input on Cures 2.0, an “effort to modernize coverage and access to life-saving cures in the United…
Current Landscape: Value Assessment Frameworks
This report analyzed seven existing U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework.
Best Ideas Aren’t Always (or Often) From Washington
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional…
AMCP Opens Comment Period for Updating Format for Manufacturer-Payor Communications
As part of its ongoing efforts to align with new federal guidance, the Academy of Managed Care Pharmacy released an updated draft of its Format for Formulary Submissions for public comment. Read more…
Integrating Data for Better Care Management
To accelerate the ability of care management programs to use data to combat rising health care costs, while ensuring patient access to innovative treatments that can improve outcomes, NPC sponsored…
NPC in Specialty Pharmacy Times: How Can We Advance Progress in Moving from Volume to Value in Health Care?
In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains that rather than trying to score news headlines, what we need is a…
Get to Know Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD
Duke Margolis-NPC Postdoctoral Health Policy Fellow Taruja Karmarkar, PhD, sat down with us to discuss her upcoming research, bridging the gap between academia and health care stakeholders, tips for…
NPC in AJPB: Working Toward Better Value in Prescription Drug Benefits Management
U.S. employers provide a vital link to health care, with more than 56 percent of them offering health insurance for their employees. However, how employers design those health benefits can vary…
Checking In With Schaeffer-NPC Postdoctoral Fellow in Health Policy, Dr. Ilene Hollin
Ilene Hollin, PhD, is entering the second year of her NPC-USC Schaeffer Center Health Policy fellowship, a post-doctoral, two-year fellowship that seeks to bridge the gap between health research and…